UCB Pharma

UCB, Biogen lupus drug scores in phase 3 trial
Pharmaphorum
Tue, 09/24/24 - 11:37 am
UCB Pharma
Biogen
systemic lupus erythematosus
clinical trials
dapirolizumab pegol
UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals
Fierce Pharma
Mon, 09/23/24 - 10:19 pm
UCB Pharma
Bimzelx
FDA
psoriatic arthritis
radiographic axial spondyloarthritis
ankylosing spondylitis
UCB sells off production plant and a clutch of older meds in China for $680M
Fierce Pharma
Mon, 08/26/24 - 11:09 am
UCB Pharma
China
UCB leads pharma in CX, according to DT Consulting survey
Medical Marketing and Media
Mon, 08/12/24 - 05:56 pm
UCB Pharma
Customer Experience
physicians
HCPs
Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB
Fierce Pharma
Fri, 04/26/24 - 11:44 am
Pfizer
UCB Pharma
WuXi AppTec
Takeda
BIO
UCB launches DTC Bimzelx ad blitz at the Oscars
Medical Marketing and Media
Sun, 03/10/24 - 08:23 pm
UCB Pharma
DTC advertising
Oscars
psoriasis
Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024
Fierce Pharma
Wed, 02/28/24 - 09:47 pm
UCB Pharma
Bimzelx
After Pfizer's exit, UCB splits from industry trade group BIO
Fierce Pharma
Sun, 01/7/24 - 04:20 pm
UCB Pharma
BIO
Pfizer
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
BioSpace
Mon, 11/13/23 - 11:58 am
ViaNautis Bio
Eli Lilly
genetic nanomedicine
UCB Pharma
funding
FDA Approves UCB’s Complement Inhibitor for Generalized Myasthenia Gravis
BioSpace
Wed, 10/18/23 - 11:22 am
UCB Pharma
Zilbrysq
myasthenia gravis
UCB stakes claim to gMG market as FDA clears Rystiggo
Pharmaphorum
Tue, 06/27/23 - 11:21 am
UCB Pharma
Rystiggo
myasthenia gravis
FDA
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
UCB partners with Ariceum for treatment of immune-related diseases and cancer
Biopharma Reporter
Fri, 05/12/23 - 11:30 am
UCB Pharma
Ariceum
R&D
radiopharmaceuticals
solid tumors
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Tue, 04/11/23 - 10:04 am
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Spotlight – following Humira in hidradenitis suppurativa
EP Vantage
Tue, 04/4/23 - 10:10 am
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Bimzelx
MoonLake Immunotherapeutics
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
EP Vantage
Tue, 03/21/23 - 09:54 am
AAD
hidradenitis suppurativa
AbbVie
Humira
UCB Pharma
Bimzelx
Acelyrin
izokibep
UCB's bimekizumab finally back on the FDA's review list after May rejection
Fierce Pharma
Wed, 12/28/22 - 08:40 pm
UCB Pharma
psoriasis
bimekizumab
FDA
Praxis ends year on high with $100M biobucks UCB deal for epilepsy medicine
Fierce Biotech
Wed, 12/14/22 - 07:40 pm
Praxis
UCB Pharma
epilepsy
PRAX-020
UCB lowers 2022 profit expectations amid Ukraine war, rising costs
Fierce Pharma
Mon, 06/27/22 - 10:09 am
UCB Pharma
Ukraine
Russia
generics
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
Sun, 05/15/22 - 11:12 pm
UCB Pharma
bimekizumab
psoriasis
FDA
JNJ

Pages